{
  "question_stem": {
    "en": "A 22-year-old woman comes to the office due to a 2-month history of chest pain with exertion. She initially had increased shortness of breath and fatigue with exercise, but recently started experiencing substernal chest pain and lightheadedness. The patient has no prior medical conditions and takes no medications. She does not use tobacco, alcohol, or recreational drugs. On physical examination, there is jugular venous distension with a prominent A wave. Heart sounds are regular; S2 is louder than S1. The lungs are clear to auscultation. There is pitting edema over both ankles. Right heart catheterization is performed and reveals increased pulmonary artery pressure and normal pulmonary capillary wedge pressure. Pharmacotherapy directed at improving pulmonary vasodilation is initiated.",
    "zh": "一名22岁的女性因2个月的劳力性胸痛前来就诊。她最初在运动时出现呼吸困难和疲劳加重，但最近开始出现胸骨后疼痛和头晕。患者无既往病史，未服用任何药物。她不吸烟、不饮酒、不吸食娱乐性药物。体格检查显示颈静脉扩张，A波明显。心音规则；S2比S1响亮。肺部听诊清澈。双踝出现凹陷性水肿。进行右心导管检查，显示肺动脉压力升高，肺毛细血管楔压正常。开始针对改善肺血管舒张的药物治疗。"
  },
  "question": {
    "en": "Which of the following effects would be most beneficial in treating this patient's condition?",
    "zh": "以下哪种作用对治疗该患者的病情最有益？"
  },
  "options": {
    "A": {
      "en": "Activation of endothelin receptors",
      "zh": "内皮素受体激活"
    },
    "B": {
      "en": "Inhibition of endogenous prostacyclin synthesis",
      "zh": "内源性前列环素合成抑制"
    },
    "C": {
      "en": "Stimulation of phosphodiesterase-5 enzyme",
      "zh": "磷酸二酯酶-5酶的刺激"
    },
    "D": {
      "en": "Stimulation of soluble guanylyl cyclase",
      "zh": "可溶性鸟苷酸环化酶的刺激"
    },
    "E": {
      "en": "Stimulation of vascular calcium channels",
      "zh": "血管钙离子通道的刺激"
    }
  },
  "correct_answer": "D",
  "explanation": {
    "en": "This patient's right heart catheterization shows elevated pulmonary arterial pressure, which is diagnostic of pulmonary hypertension (mean pulmonary arterial pressure ≥25 mm Hg). Patients typically have a loud pulmonic component of S2 and can develop jugular venous distension and peripheral edema due to right-sided heart failure. Normal pulmonary capillary wedge pressure (estimate of left atrial pressure) rules out left-sided heart failure as the cause of this patient's pulmonary hypertension.\n\nRelatively young patients with pulmonary hypertension most commonly have pulmonary arterial hypertension (PAH), which primarily results from endothelial dysfunction and pulmonary vascular remodeling. Genetic predisposition, connective tissue disease, or HIV infection can lead to an imbalance in vasoconstrictive/proliferative mediators relative to vasodilative/antiproliferative mediators, leading to increased pulmonary vascular resistance. Treatment of PAH is mainly targeted at restoring the balance of these mediators.\n\nNitric oxide is an important vasodilative/antiproliferative mediator that is decreased in PAH. In the vascular endothelium, nitric oxide activates soluble guanylyl cyclase, which leads to increased synthesis of cyclic GMP (cGMP), resulting in vasodilation and inhibition of smooth muscle proliferation. Therefore, agents that stimulate soluble guanylyl cyclase (eg, riociguat) mimic the effects of nitric oxide and are effective treatment for PAH.\n\n(Choice A) Endothelin is an important vasoconstrictor that is increased in PAH. Activation of endothelin receptors increases pulmonary arterial vasoconstriction and smooth muscle cell proliferation and worsens PAH. Therefore, endothelin receptor antagonists (eg, bosentan, ambrisentan) are useful in treating PAH.\n\n(Choice B) Prostacyclin levels are typically decreased in PAH. Prostacyclin causes pulmonary arterial vasodilation and inhibits smooth muscle cell proliferation; therefore, inhibition of endogenous prostacyclin synthesis would worsen PAH.\n\n(Choice C) Phosphodiesterase-5 inhibitors (eg, sildenafil) increase cGMP concentration, leading to enhanced nitric oxide activity that helps improve PAH. Stimulation of phosphodiesterase-5 would likely worsen PAH.\n\n(Choice E) Calcium channel blockers (eg, nifedipine, diltiazem) are helpful in some patients with PAH, but stimulation of calcium channels will cause vasoconstriction and worsen PAH.\n\nEducational objective:\nIn the vascular endothelium, nitric oxide activates soluble guanylyl cyclase, which leads to increased synthesis of cyclic GMP, resulting in vasodilation and inhibition of smooth muscle proliferation. Pulmonary arterial hypertension (PAH) results from endothelial dysfunction leading to an imbalance of chemical mediators, including a decrease in nitric oxide. Stimulation of soluble guanylyl cyclase mimics the function of nitric oxide and is an effective treatment for PAH.",
    "zh": "该患者的右心导管检查显示肺动脉压力升高，诊断为肺动脉高压（平均肺动脉压力≥25 mmHg）。患者通常有响亮的S2肺动脉成分，并可由于右心衰竭而出现颈静脉扩张和周围水肿。正常的肺毛细血管楔压（左心房压的估计值）排除了左心衰竭是该患者肺动脉高压的原因。\n\n患有肺动脉高压的相对年轻患者最常见的是肺动脉高压（PAH），这主要由内皮功能障碍和肺血管重塑引起。遗传易感性、结缔组织疾病或HIV感染可导致血管收缩/增殖介质与血管舒张/抗增殖介质失衡，导致肺血管阻力增加。PAH的治疗主要针对恢复这些介质的平衡。\n\n一氧化氮是一种重要的血管舒张/抗增殖介质，在PAH中减少。在血管内皮中，一氧化氮激活可溶性鸟苷酸环化酶，从而导致环磷酸鸟苷（cGMP）的合成增加，从而导致血管舒张和抑制平滑肌增殖。因此，刺激可溶性鸟苷酸环化酶的药物（例如，利奥西呱）模拟一氧化氮的作用，是PAH的有效治疗方法。\n\n（选项A）内皮素是一种重要的血管收缩剂，在PAH中增加。激活内皮素受体可增加肺动脉血管收缩和平滑肌细胞增殖，并使PAH恶化。因此，内皮素受体拮抗剂（例如，波生坦、安立生坦）对治疗PAH有益。\n\n（选项B）前列环素水平在PAH中通常降低。前列环素引起肺动脉血管舒张并抑制平滑肌细胞增殖；因此，抑制内源性前列环素合成会使PAH恶化。\n\n（选项C）磷酸二酯酶-5抑制剂（例如，西地那非）增加cGMP浓度，从而增强一氧化氮活性，有助于改善PAH。刺激磷酸二酯酶-5可能会使PAH恶化。\n\n（选项E）钙通道阻滞剂（例如，硝苯地平、地尔硫卓）对某些PAH患者有帮助，但刺激钙通道会导致血管收缩并使PAH恶化。\n\n教育目标：\n在血管内皮中，一氧化氮激活可溶性鸟苷酸环化酶，从而导致环磷酸鸟苷（cGMP）的合成增加，从而导致血管舒张和抑制平滑肌增殖。肺动脉高压（PAH）是由内皮功能障碍引起的，导致化学介质失衡，包括一氧化氮的减少。刺激可溶性鸟苷酸环化酶模拟一氧化氮的功能，是PAH的有效治疗方法。"
  },
  "summary": {
    "en": "This question tests the understanding of the pathophysiology of pulmonary arterial hypertension (PAH) and the mechanisms of action of various pharmacologic agents used in its treatment. Specifically, it assesses knowledge of the nitric oxide-soluble guanylyl cyclase-cGMP pathway and its role in vasodilation and smooth muscle proliferation.\n\nTo solve this question, one must first identify the diagnosis of pulmonary arterial hypertension based on the clinical presentation and right heart catheterization findings. Then, recall the key signaling pathways involved in regulating pulmonary vascular tone and smooth muscle growth. Finally, evaluate how each option affects these pathways to determine which would be most beneficial in treating PAH.",
    "zh": "此题考察对肺动脉高压（PAH）的病理生理学以及用于治疗的各种药理学药物的作用机制的理解。具体来说，它评估了对一氧化氮-可溶性鸟苷酸环化酶-cGMP通路的了解及其在血管舒张和平滑肌增殖中的作用。\n\n要解决这个问题，首先必须根据临床表现和右心导管检查结果确定肺动脉高压的诊断。然后，回忆参与调节肺血管张力和平滑肌生长的关键信号通路。最后，评估每个选项如何影响这些通路，以确定哪一个对治疗PAH最有益。"
  },
  "tags": "Pulmonary hypertension; Pulmonary arterial hypertension; Right heart catheterization; Vasodilation; Soluble guanylyl cyclase; Nitric oxide; Cyclic GMP; Endothelial dysfunction; Pulmonary vascular remodeling; Pharmacotherapy",
  "category": "Miscellanous",
  "question_id": "14960",
  "has_exhibits": true,
  "exhibit_count": 2,
  "exhibit_files": [
    "image1.jpg",
    "image2.jpg"
  ],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Miscellanous 23\\14960",
  "extracted_at": "2025-11-05T19:25:10.132111",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 2,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T18:14:26.876557",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}